Genmab A/S (GMAB) Stock Forecast & Price Target

GMAB Forecast - Frequently Asked Questions

What is Genmab A/S's forecast for 2025?

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Genmab A/S is $40.80, with a high forecast of $48.00 and a low forecast of $27.00.

Should I buy or sell Genmab A/S stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There is currently 1 sell rating, 2 hold ratings, 7 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GMAB shares.

Does Genmab A/S's stock price have much upside?

According to analysts, Genmab A/S's stock has a predicted upside of 21.57% based on their 12-month stock forecasts.

Has Genmab A/S been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, Genmab A/S's stock had 2 upgrades and 1 downgrade by analysts.

What analysts cover Genmab A/S?

Genmab A/S has been rated by research analysts at Guggenheim, HC Wainwright, Truist Financial, Weiss Ratings, and Zacks Research in the past 90 days.

Do Wall Street analysts like Genmab A/S more than its competitors?

Analysts like Genmab A/S more than other "medical" companies. The consensus rating for Genmab A/S is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how GMAB compares to other companies.